The FDA's Pharmacy Compounding Advisory Committee voted 8-6 with one abstention on July 23, 2026, to recommend adding BPC-157 to the Section 503A bulk drug substances list for evaluation in ulcerative colitis, overriding staff concerns over limited human safety and efficacy data. This non-binding step followed the peptide's April 2026 removal from Category 2 restrictions after nomination withdrawal. Final placement on the affirmative list requires agency rulemaking, including proposal, public comment, and a potential final rule—processes that typically extend months beyond an advisory vote. Health Secretary Robert F. Kennedy Jr.'s public support for expanded peptide access has shaped the regulatory environment, though the FDA retains discretion to accept or reject the recommendation. Ongoing clinical trials and any subsequent agency actions within the resolution window remain key variables for compounding eligibility.
Polymarket डेटा का संदर्भ देने वाला प्रयोगात्मक AI-जनरेटेड सारांश। यह ट्रेडिंग सलाह नहीं है और इस बाज़ार के समाधान में कोई भूमिका नहीं निभाता। · अपडेट किया गयानया
31 दिस, 2026
31 दिसंबर, 2026
59%
$4,143 वॉल्यूम
31 दिसंबर, 2026
$2,141 वॉल्यूम
59%
This market will resolve to “Yes” if the Food and Drug Administration (FDA) announces that it has reclassified or will reclassify BPC-157 to Category 1 of the Bulk Drug Substances List by the listed date, 11:59 PM ET. Otherwise, this market will resolve to “No”.
A qualifying announcement must be official and public. Any rumored or private statements of intention will not qualify.
Any announcement that the drug has been reclassified to Category 1 will qualify. Any announcement within this market’s timeframe of future intention to reclassify to Category 1 will qualify regardless of whether the reclassification has happened by the listed date.
A qualifying reclassification must be to Category 1 of the Bulk Drug Substances List or an equivalent classification that allows interim compounding of the drug. Removal from a different category will not qualify.
The resolution source for this market will be official statements from the FDA; however, a consensus of credible reporting will also be used.The FDA's Pharmacy Compounding Advisory Committee voted 8-6 with one abstention on July 23, 2026, to recommend adding BPC-157 to the Section 503A bulk drug substances list for evaluation in ulcerative colitis, overriding staff concerns over limited human safety and efficacy data. This non-binding step followed the peptide's April 2026 removal from Category 2 restrictions after nomination withdrawal. Final placement on the affirmative list requires agency rulemaking, including proposal, public comment, and a potential final rule—processes that typically extend months beyond an advisory vote. Health Secretary Robert F. Kennedy Jr.'s public support for expanded peptide access has shaped the regulatory environment, though the FDA retains discretion to accept or reject the recommendation. Ongoing clinical trials and any subsequent agency actions within the resolution window remain key variables for compounding eligibility.
This market will resolve to “Yes” if the Food and Drug Administration (FDA) announces that it has reclassified or will reclassify BPC-157 to Category 1 of the Bulk Drug Substances List by the listed date, 11:59 PM ET. Otherwise, this market will resolve to “No”.
A qualifying announcement must be official and public. Any rumored or private statements of intention will not qualify.
Any announcement that the drug has been reclassified to Category 1 will qualify. Any announcement within this market’s timeframe of future intention to reclassify to Category 1 will qualify regardless of whether the reclassification has happened by the listed date.
A qualifying reclassification must be to Category 1 of the Bulk Drug Substances List or an equivalent classification that allows interim compounding of the drug. Removal from a different category will not qualify.
The resolution source for this market will be official statements from the FDA; however, a consensus of credible reporting will also be used.
A qualifying announcement must be official and public. Any rumored or private statements of intention will not qualify.
Any announcement that the drug has been reclassified to Category 1 will qualify. Any announcement within this market’s timeframe of future intention to reclassify to Category 1 will qualify regardless of whether the reclassification has happened by the listed date.
A qualifying reclassification must be to Category 1 of the Bulk Drug Substances List or an equivalent classification that allows interim compounding of the drug. Removal from a different category will not qualify.
The resolution source for this market will be official statements from the FDA; however, a consensus of credible reporting will also be used.
बाज़ार खुला: Jun 22, 2026, 10:10 PM ET
वॉल्यूम
$4,143समाप्ति तिथि
1 जन, 2027बाज़ार खुला
Jun 22, 2026, 10:10 PM ETरिज़ॉल्वर
0x65070BE91...This market will resolve to “Yes” if the Food and Drug Administration (FDA) announces that it has reclassified or will reclassify BPC-157 to Category 1 of the Bulk Drug Substances List by the listed date, 11:59 PM ET. Otherwise, this market will resolve to “No”.
A qualifying announcement must be official and public. Any rumored or private statements of intention will not qualify.
Any announcement that the drug has been reclassified to Category 1 will qualify. Any announcement within this market’s timeframe of future intention to reclassify to Category 1 will qualify regardless of whether the reclassification has happened by the listed date.
A qualifying reclassification must be to Category 1 of the Bulk Drug Substances List or an equivalent classification that allows interim compounding of the drug. Removal from a different category will not qualify.
The resolution source for this market will be official statements from the FDA; however, a consensus of credible reporting will also be used.The FDA's Pharmacy Compounding Advisory Committee voted 8-6 with one abstention on July 23, 2026, to recommend adding BPC-157 to the Section 503A bulk drug substances list for evaluation in ulcerative colitis, overriding staff concerns over limited human safety and efficacy data. This non-binding step followed the peptide's April 2026 removal from Category 2 restrictions after nomination withdrawal. Final placement on the affirmative list requires agency rulemaking, including proposal, public comment, and a potential final rule—processes that typically extend months beyond an advisory vote. Health Secretary Robert F. Kennedy Jr.'s public support for expanded peptide access has shaped the regulatory environment, though the FDA retains discretion to accept or reject the recommendation. Ongoing clinical trials and any subsequent agency actions within the resolution window remain key variables for compounding eligibility.
This market will resolve to “Yes” if the Food and Drug Administration (FDA) announces that it has reclassified or will reclassify BPC-157 to Category 1 of the Bulk Drug Substances List by the listed date, 11:59 PM ET. Otherwise, this market will resolve to “No”.
A qualifying announcement must be official and public. Any rumored or private statements of intention will not qualify.
Any announcement that the drug has been reclassified to Category 1 will qualify. Any announcement within this market’s timeframe of future intention to reclassify to Category 1 will qualify regardless of whether the reclassification has happened by the listed date.
A qualifying reclassification must be to Category 1 of the Bulk Drug Substances List or an equivalent classification that allows interim compounding of the drug. Removal from a different category will not qualify.
The resolution source for this market will be official statements from the FDA; however, a consensus of credible reporting will also be used.
A qualifying announcement must be official and public. Any rumored or private statements of intention will not qualify.
Any announcement that the drug has been reclassified to Category 1 will qualify. Any announcement within this market’s timeframe of future intention to reclassify to Category 1 will qualify regardless of whether the reclassification has happened by the listed date.
A qualifying reclassification must be to Category 1 of the Bulk Drug Substances List or an equivalent classification that allows interim compounding of the drug. Removal from a different category will not qualify.
The resolution source for this market will be official statements from the FDA; however, a consensus of credible reporting will also be used.
वॉल्यूम
$4,143समाप्ति तिथि
1 जन, 2027बाज़ार खुला
Jun 22, 2026, 10:10 PM ETरिज़ॉल्वर
0x65070BE91...The FDA's Pharmacy Compounding Advisory Committee voted 8-6 with one abstention on July 23, 2026, to recommend adding BPC-157 to the Section 503A bulk drug substances list for evaluation in ulcerative colitis, overriding staff concerns over limited human safety and efficacy data. This non-binding step followed the peptide's April 2026 removal from Category 2 restrictions after nomination withdrawal. Final placement on the affirmative list requires agency rulemaking, including proposal, public comment, and a potential final rule—processes that typically extend months beyond an advisory vote. Health Secretary Robert F. Kennedy Jr.'s public support for expanded peptide access has shaped the regulatory environment, though the FDA retains discretion to accept or reject the recommendation. Ongoing clinical trials and any subsequent agency actions within the resolution window remain key variables for compounding eligibility.
Polymarket डेटा का संदर्भ देने वाला प्रयोगात्मक AI-जनरेटेड सारांश। यह ट्रेडिंग सलाह नहीं है और इस बाज़ार के समाधान में कोई भूमिका नहीं निभाता। · अपडेट किया गया
बाहरी लिंक से सावधान रहें।
बाहरी लिंक से सावधान रहें।
अक्सर पूछे जाने वाले प्रश्न